Mechanisms of Immune Dysfunction after Trauma and Surgical Sepsis
Mechanisms of Immune Dysfunction after Trauma and Surgical Sepsis
批准号:
10623487
负责人:
TIMOTHY R BILLIAR
金额:
$69.72万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
未结题
起止时间:
2018-06-01 至 2028-05-31
关键词:
AcuteAgeAtlasesBloodBlood specimenCellsCessation of lifeChromatinCirculationComparative StudyCritical IllnessDataData SetDevelopmentEpigenetic ProcessFunctional disorderFundingGene ExpressionGenomicsHemorrhagic ShockHumanImmuneImmune System DiseasesImmunosuppressionLeadLipidsMeasuresMorbidity - disease rateMultiomic DataOperative Surgical ProceduresOrganOutcomePatientsPatternPeripheral Blood Mononuclear CellPolycombPredispositionProteinsPublishingResearchResourcesSecondary toSepsisTechnologyTimeTranslatingTraumaTrauma patientWorkbiomarker identificationcell typederepressionimproved outcomeinsightmouse modelmultidimensional datamultiple omicsnew therapeutic targetnovelonline resourcepatient stratificationpredictive markerprotein expressionresponsesecondary infectionsevere injurysexsystemic inflammatory responsetargeted treatmenttherapeutic target
中文摘要
项目摘要/摘要
创伤和外科脓毒症是全世界发病率和死亡率的主要原因之一。这两个都是急性的
侮辱可能导致免疫功能障碍,然后导致持续的危重疾病状态。这种免疫力
功能障碍表现为过度的全身炎症反应,可导致器官功能障碍;
同时抑制免疫防御,使患者容易受到继发感染。
然而,我们缺乏关于人类如何应对严重伤害的全面和综合的观点,以及更多
重要的是,这些反应在快速康复的患者和死亡和/或死亡的患者之间有何不同
持续发展的危重病。单细胞多重组学和血液分析的研究进展
平台,多重组学现在使表征跨越广泛的细胞状态和
在循环的生物分子景观中的模式深入到很深。在上一个融资周期中,我们
第一个对来自中国的血液样本进行单细胞基因组学和大规模多平台、多组学
伤势严重的病人。这项已发表的工作确定了许多新的发现,包括早期的大规模
将细胞成分释放到创伤患者的循环中,这些患者要么经历复杂的过程,要么死亡。
此外,对PBMC的开放染色质分析发现,仍处于危重状态的患者也有全身性
表观遗传学变化在早期免疫细胞类型中很明显,代表着多梳靶的抑制。在……里面
在一项研究中,我们将反向翻译这些和其他新发现来自我们最初的人类
对失血性休克和创伤小鼠模型的多组学分析以寻求潜在的治疗方法
目标。在另一项研究中,我们将扩展我们对多组数据的分析,以创建一份血液图谱
人类创伤反应。这个在线资源将包含关于循环免疫细胞范围的数据
严重损伤后常见的状态,并将这些与高维度的纵向变化相结合
循环蛋白质、脂质和其他代谢物的数据集。我们将应用最先进的计算技术
根据结果、治疗方法、年龄分层确定生物标记物和治疗靶点的策略
还有性爱。我们将把我们的结果与在脓毒症中发表的类似研究进行比较。除了这些发现和
我们的分析将产生机械性的见解,我们希望我们提供的资源将促进比较
对我们的数据集进行研究和进一步分析。
英文摘要
Project Summary/Abstract
Trauma and Surgical Sepsis are among the leading causes of morbidity and death worldwide. Both of these acute
insults can lead to immune dysfunction that then contributes to a state of persistent critical illness. This immune
dysfunction is manifested by an excessive systemic inflammatory response that can lead to organ dysfunction;
and a simultaneous suppression of immune defenses that renders patients susceptible to secondary infections.
However, we lack a comprehensive and integrated view of how humans respond to severe injury, and more
importantly, how these responses differ between patients that recover quickly vs. those that die and/or
development persistent critical illness. Advances in single cell multiomics and blood analysis using multi-
platform, multiomics now makes it possible to characterize changes across a broad range of cell states and
patterns within the circulating biomolecule landscape to great depth. In the previous funding cycle, we were
the first to perform single cell genomics and large-scale multi-platform, multiomics on blood samples from
severely injured patients. This published work identified many novel findings, including the early massive
release of cellular constituents into the circulation of trauma patients that follow a complicated course or die.
In addition, open chromatin analysis of PBMC found that patients who remain critically ill also have global
epigenetic changes evident early across immune cell types, representing de-repression of polycomb targets. In
one line of research, we will reverse translate the these and other novel findings from our initial human
multiomic analyses into our mouse model of hemorrhagic shock and trauma to pursue potential therapeutic
targets. In another line of research, we will extend our analysis of multiomic data to create a Blood Atlas of the
human trauma response. This online resource will incorporate data on the range of circulating immune cell
states commonly seen after severe injury and integrate these with the longitudinal changes in high dimensional
datasets of circulating proteins, lipids and other metabolites. We will apply state-of-the-art computational
strategies to identify biomarkers and therapeutic targets with patients stratified by outcomes, treatments, age
and sex. We will compare our results with similar published studies in sepsis. In addition to the discoveries and
mechanistic insights our analysis will yield, we hope that the resources we provide will stimulate comparative
studies and further analyses of our datasets.
期刊论文(8)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1172/jci127542
发表时间:
2019-08
期刊:
The Journal of clinical investigation
影响因子:
--
作者:
[Li Xu;Yiming Li;Chenxuan Yang;P. Loughran;H. Liao;R. Hoffman;T. Billiar;M. Deng]
通讯作者:
Li Xu;Yiming Li;Chenxuan Yang;P. Loughran;H. Liao;R. Hoffman;T. Billiar;M. Deng
DOI:
10.1016/j.isci.2023.108333
发表时间:
2023-12-15
期刊:
ISCIENCE
影响因子:
5.8
作者:
[El-Dehaibi, Fayten, Zamora, Ruben, Radder, Josiah, Yin, Jinling, Shah, Ashti M., Namas, Rami A., Situ, Michelle, Zhao, Yanwu, Bain, William, Morris, Alison, Mcverry, Bryan J., Barclay, Derek A., Billiar, Timothy R., Zhang, Yingze, Kitsios, Georgios D., Vodovotz, Yoram]
通讯作者:
Vodovotz, Yoram
Targeting inflammation in traumatic injury: entering a new era.
针对创伤性损伤中的炎症:进入新时代。
DOI:
10.1007/s00134-023-07152-2
发表时间:
2023
期刊:
Intensive care medicine
影响因子:
38.9
作者:
[Billiar,TimothyR, Hunt,BeverleyJ, Bailly,Sebastien]
通讯作者:
Bailly,Sebastien
DOI:
10.1097/shk.0000000000001958
发表时间:
2022-07-01
期刊:
Shock (Augusta, Ga.)
影响因子:
--
作者:
[]
通讯作者:
Lipidomic Signatures Align with Inflammatory Patterns and Outcomes in Critical Illness.
脂质组学特征与危重疾病的炎症模式和结果一致。
DOI:
10.21203/rs.3.rs-106579/v1
发表时间:
2021
期刊:
Research square
影响因子:
--
作者:
[Wu,Junru, Cyr,Anthony, Gruen,DanielleS, Lovelace,TylerC, Benos,PanayiotisV, Chen,Tianmeng, Guyette,FrancisX, Yazer,MarkH, Daley,BrianJ, Miller,RichardS, Harbrecht,BrianG, Claridge,JeffreyA, Phelan,HerbA, Zuckerbraun,BrianS, Neal,]
通讯作者:
Neal,
Mechanisms of Immune Dysfunction after Trauma and Surgical Sepsis
-
批准号:10183268
-
项目类别:
-
资助金额:$63.28万
-
财政年份:2018
-
负责人:TIMOTHY R BILLIAR
-
依托单位:
Mechanisms of Immune Dysfunction after Trauma and Surgical Sepsis
-
批准号:10403953
-
项目类别:
-
资助金额:$63.28万
-
财政年份:2018
-
负责人:TIMOTHY R BILLIAR
-
依托单位:
Immunometabolism in Sepsis
-
批准号:9110280
-
项目类别:
-
资助金额:$30.42万
-
财政年份:2015
-
负责人:TIMOTHY R BILLIAR
-
依托单位:
Immunometabolism in Sepsis
-
批准号:9274994
-
项目类别:
-
资助金额:$30.42万
-
财政年份:2015
-
负责人:TIMOTHY R BILLIAR
-
依托单位:
Immunometabolism in Sepsis
-
批准号:8937151
-
项目类别:
-
资助金额:$30.42万
-
财政年份:2015
-
负责人:TIMOTHY R BILLIAR
-
依托单位:
Core A: Administrative Core
-
批准号:7751473
-
项目类别:
-
资助金额:$3.83万
-
财政年份:2009
-
负责人:TIMOTHY R BILLIAR
-
依托单位:
Project 1: Initiation of Inflammation in Hemorrhagic Shock
-
批准号:7751460
-
项目类别:
-
资助金额:$25.71万
-
财政年份:2009
-
负责人:TIMOTHY R BILLIAR
-
依托单位:
Core B: Animal Models Core
-
批准号:7751475
-
项目类别:
-
资助金额:$29.23万
-
财政年份:2009
-
负责人:TIMOTHY R BILLIAR
-
依托单位:
Trauma and Injury Excellence in Education on Research (TralnEER) Program
-
批准号:7216886
-
项目类别:
-
资助金额:$14.47万
-
财政年份:2006
-
负责人:TIMOTHY R BILLIAR
-
依托单位:
Trauma and Injury Excellence in Education on Research (TralnEER) Program
-
批准号:7585779
-
项目类别:
-
资助金额:$14.47万
-
财政年份:2006
-
负责人:TIMOTHY R BILLIAR
-
依托单位:
Trauma and Injury Excellence in Education on Research (TralnEER) Program
-
批准号:7117070
-
项目类别:
-
资助金额:$16.59万
-
财政年份:2006
-
负责人:TIMOTHY R BILLIAR
-
依托单位:
iNOS Gene Therapy to Prevent Allograft Vasculopathy
-
批准号:7139403
-
项目类别:
-
资助金额:$21.6万
-
财政年份:2005
-
负责人:TIMOTHY R BILLIAR
-
依托单位:
CORE--ANIMAL MODEL FACILITY/Core B
-
批准号:6829219
-
项目类别:
-
资助金额:$23.68万
-
财政年份:2004
-
负责人:TIMOTHY R BILLIAR
-
依托单位:
INITIATION OF INFLAMMATION IN HEMORRHAGIC SHOCK
-
批准号:6829215
-
项目类别:
-
资助金额:$22.21万
-
财政年份:2004
-
负责人:TIMOTHY R BILLIAR
-
依托单位:
ADMINISTRATIVE CORE
-
批准号:6861606
-
项目类别:
-
资助金额:$4.03万
-
财政年份:2004
-
负责人:TIMOTHY R BILLIAR
-
依托单位:
CD14 AND INFLAMMATION IN HEMORRHAGIC SHOCK
-
批准号:6107772
-
项目类别:
-
资助金额:$11.19万
-
财政年份:1999
-
负责人:TIMOTHY R BILLIAR
-
依托单位:
CORE--ANIMAL MODELS FACILITY
-
批准号:6107777
-
项目类别:
-
资助金额:$11.19万
-
财政年份:1999
-
负责人:TIMOTHY R BILLIAR
-
依托单位:
CD14 AND INFLAMMATION IN HEMORRHAGIC SHOCK
-
批准号:6271865
-
项目类别:
-
资助金额:$10.87万
-
财政年份:1998
-
负责人:TIMOTHY R BILLIAR
-
依托单位:
Molecular Biology of Hemorrhagic Shock
-
批准号:7694077
-
项目类别:
-
资助金额:$153.1万
-
财政年份:1998
-
负责人:TIMOTHY R BILLIAR
-
依托单位:
Molecular Biology of Hemorrhagic Shock
-
批准号:8294845
-
项目类别:
-
资助金额:$120.71万
-
财政年份:1998
-
负责人:TIMOTHY R BILLIAR
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: